Senior Vice President, Business Development & Strategy, GATC Health
Mark Flather serves as Senior Vice President, Corporate Strategy and Business Development for GATC Health. Prior to joining GATC in January of 2026, Mr. Flather served as Senior Vice President, Corporate Strategy and Capital Markets for publicly traded Vistagen Therapeutics, Inc., a late-stage biopharmaceutical company developing novel therapeutics in the CNS space.
Mr. Flather has more than 30 years of capital markets experience in various capacities on the buy-side, the sell-side, and with two corporations in the healthcare industry. Prior to joining Vistagen in March 2021, he managed Investor Relations and Corporate Communications for Adamis Pharmaceuticals, where he was named on three different design patents for the company’s FDA-approved injection device platform. Before Adamis, Mr. Flather served as Vice President of Investor Relations and Outreach at MZ Group, the world’s largest independent global IR consulting firm. He also spent almost a decade as the Chief Operating Officer, Head Equity Trader, Investor Relations Director, and Research Analyst for Hermes Advisors, a small to mid-cap equity hedge fund. He began his sell-side experience on the institutional sales and trading desk of the investment bank Alex. Brown and Sons. Mr. Flather holds a B.A. in Psychology from U.C. Santa Barbara.